FindTrial
Sign In

Early Warning Research on Cardiotoxicity Induced by Anthracyclines Based on Peripheral Blood Lymphocyte-related Immune Indicators

Early Warning Research on Cardiotoxicity Induced by Anthracyclines Based on Peripheral Blood Lymphocyte-related Immune Indicators

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112670
Enrollment
Unknown
Registered
2025-11-18
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

The group of breast cancer patients who received treatment with anthracycline drugs:None

Sponsors

Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Female patients diagnosed with breast cancer and receiving treatment with anthracycline drugs (such as doxorubicin, idarubicin, epirubicin, mitoxantrone, etc.); 2.Age range: 18 - 80 years old.

Exclusion criteria

Exclusion criteria: 1.History of severe cardiovascular diseases (myocardial infarction, heart failure, severe arrhythmia, etc.); 2.Severe liver and kidney diseases; 3.Obvious infections; 4.Severe blood system diseases.

Design outcomes

Primary

MeasureTime frame
Left ventricular ejection fraction (LVEF);—

Countries

China

Contacts

Public ContactShilan Zhang

Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine

cardio_shilan521@163.com+86 151 9736 2837

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026